Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697409 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2CRBNALDH1A1LMNAAKR1C3 | |
| SCHEMBL10431444 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2CRBNALDH1A1LMNAAKR1C3 | |
| SCHEMBL983030 | 0.78 | CA1 (0.40) | SMN1; SMN2CRBNLMNATSHR | |
| SCHEMBL14275649 | 0.76 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1LMNACYP3A4CYP2C9 | |
| SCHEMBL12121152 | 0.75 | PTPN11 (0.32) | CRBN | |
| SCHEMBL12183870 | 0.74 | SMN1; SMN2 (0.31) | SMN1; SMN2CRBN | |
| SCHEMBL12183005 | 0.71 | ALDH1A1 (0.30) | ALDH1A1LMNA | |
| SCHEMBL360858 | 0.70 | GAA (0.35) | SMN1; SMN2CRBNALDH1A1 | |
| SCHEMBL8974251 | 0.68 | SMN1; SMN2 (0.42) | SMN1; SMN2CRBNALDH1A1LMNACYP3A4 | |
| SCHEMBL13841505 | 0.67 | CTRB1 (0.44) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | SMN1; SMN2 2266/4885CRBN 3436/4885ALDH1A1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.